



*Supplement of*

## **Osteosynthesis-associated infection of the lower limbs by multidrug-resistant and extensively drug-resistant Gram-negative bacteria: a multicentre cohort study**

**Efthymia Giannitsioti et al.**

*Correspondence to:* Efthymia Giannitsioti (gianiemi@hotmail.com)

The copyright of individual parts of the supplement might differ from the article licence.

1      **Supplementary table S1. Clinical characteristics and antimicrobial  
2      treatment in patients with OAI according to the type of surgery**

3

Variables, n (%)	Implant removal n= 27	Implant retention with debridement, n= 30	All procedures n=57	p
<b>Age (+/-SD) years</b>	56.59 (21.05)	56.03(22.54)	56.30(21.65)	0.923
<b>Male</b>	10(37)	13(43.3)	23(40.4)	0.788
<b>Female</b>	17(63)	17(56.7)	34(59.6)	
<b>Comorbidities <sup>1</sup></b>	8(29.6)	9(30)	17(29.8)	>0.999
<b>History of trauma</b>	24(88.9)	26(86.7)	50(87.7)	>0.999
<b>Prior surgery for implant infection</b>	9(33.3)	10(33.3)	19(33.3)	>0.999
<b>Early</b>	8(29.6)	20(66.7)	28(49.1)	<b>0.008</b>
<b>Late infection <sup>2</sup></b>	19(70.4)	10(33.3)	29(50.9)	
<b>Fever</b>	5(18.5)	6(20)	11(19.3)	>0.999
<b>Soft tissue infection</b>	16(59.3)	18(60)	34(59.6)	>0.999
<b>Sinus tract</b>	9(33.3)	15(50)	24(42.1)	0.284
<b>Location</b>				
<b>-hip, femur</b>	13(48.1)	15(50)	28(49.9)	>0.999
<b>-knee, tibia, foot</b>	14(51.9)	15(50)	29(50.1)	
<b>MDR GNB</b>	21(77.8)	23(76.7)	44(77.2)	>0.999
<b>XDR GNB <sup>3</sup></b>	6(22.2)	7(23.3)	13(22.8)	
<b><i>Pseudomonas aeruginosa</i></b>	6(22.2)	8(26.7)	14(24.6)	0.765
<b>Use of fluoroquinolones</b>	5(18.5)	3(10)	8(14)	0.457
<b>Use of carbapenems</b>	17(63)	15(50)	32(56.1)	0.425
<b>Use of colistin</b>	5(18.5)	6(20)	11(19.3)	>0.999
<b>Combined antibiotics</b>	15(55.6)	22(73.3)	37(64.9)	0.178
<b>Antibiotics &gt; 42 days</b>	13(48.1)	20(66.7)	33(57.9)	0.187
<b>More than one surgical procedure during follow-up</b>	6(22.2)	8 (26.7)	14(24.6)	0.765
<b>Remission of infection</b>	16(59.2)	13(43.3)	29(50.9)	0.292

4

5      **Footnotes**

6      <sup>1</sup> Comorbidities: Diabetes mellitus, Chronic renal failure, Cardiovascular Diseases  
7      (heart disease, stroke), COPD (Chronic Obstructive Pulmonary Disease), Malignancy,  
8      Rheumatologic diseases

9      <sup>2</sup> infection onset within the first 4 weeks (early) or beyond 4 weeks (late)

10     following index osteosynthesis of any bone of the lower extremities.

11     <sup>3</sup> MDR = Multi Drug Resistant, XDR= Extensively Drug Resistant, GNB=Gram Negative  
12     Bacteria

13     <sup>4</sup> Remission of infection: no sign of infection during a 24-month follow up